escitalopram has been researched along with Depression in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 45 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, CW; Kao, HY; Lin, PY; Tseng, WT; Wang, LJ; Yang, YH | 1 |
| O'Leary, K | 1 |
| Ang, SY; Bauereiß, N; Baumeister, H; Bendig, E; Bengel, J; Lee, EJ; Tully, PJ | 1 |
| Bhat, V; Demchenko, I; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Ravindran, AV; Rotzinger, S | 1 |
| Dong, C; Fujita, A; Fujita, Y; Hashimoto, K; Hino, N; Iijima, M; Tian, Z | 1 |
| Allen, TA; Blier, P; Dhami, P; Farzan, F; Foster, JA; Frey, BN; Kennedy, SH; Kloiber, S; Lam, RW; MacQueen, G; Milev, R; Müller, DJ; Parikh, SV; Quilty, LC; Rotzinger, S; Schwartzmann, B; Soares, CN; Strother, SC; Turecki, G; Uher, R | 1 |
| Strous, JFM | 1 |
| Feng, RF; Guo, L; Ji, X; Jiao, JW; Li, MM; Ma, R; Wang, P; Zhang, ZX | 1 |
| Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S | 1 |
| Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB | 1 |
| Behle, N; Brendel, M; Chrobok, A; Karch, S; Keeser, D; Koch, W; Koller, G; Krause, D; Manz, KM; Pogarell, O; Rominger, A | 1 |
| Alexopoulos, GS; Avari, J; Dunlop, K; Gunning, FM; Hoptman, MJ; Ilieva, I; Oberlin, LE; Victoria, LW | 1 |
| Joca, SRL; Lisboa, SF; Sartim, AG; Silveira, KM; Vieira, L; Wegener, G | 1 |
| Cai, JF; Chen, GB; He, JK; Hou, XB; Jiao, Y; Jin, GX; Liu, Y; Qin, ZS; Rong, PJ; Shi, L; Wang, Y; Wong, YK; Xiao, HB; Xiao, X; Xu, FQ; Yang, XJ; Zhang, JN; Zhang, LL; Zhang, SY; Zhang, ZJ; Zhao, YY; Zheng, Y | 1 |
| Ahmed, R; Albert, K; Andrews, P; Begnoche, P; Boyd, BD; Elson, D; Kang, H; Landman, BA; Szymkowicz, SM; Taylor, WD; Vega, J | 1 |
| Armand, S; Frokjaer, VG; Giraldi, A; Joergensen, MB; Knudsen, GM; Nielsen, JH; Stenbaek, DS; Weber, S | 1 |
| Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ | 1 |
| Amann, F; Brand, J; Eichentopf, L; Gründer, G; Hart, XM | 1 |
| Asanova, AE; Assonov, DO; Khaustova, OO; Omelyanovich, VY | 1 |
| Cui, X; Wang, L; Xu, Y; Zhou, J; Zhu, H | 1 |
| Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B | 1 |
| Christensen, KS; Gasse, C; Ishtiak-Ahmed, K | 1 |
| Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Chen, YM; Guan, W; Huang, J; Jiang, B; Li, WY; Shi, TS; Xu, DW | 1 |
| Zhang, J; Zhao, Z; Zheng, X | 1 |
| Aljabali, AAA; Alqudah, A; Altaber, S; Gammoh, O; Ibrahim, A; Qnais, E; Tambuwala, MM | 1 |
| Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD | 1 |
| Liu, M; Lu, N; Zhang, L | 1 |
| Bhatele, P; Chand Sarangi, S; Dwivedi, R; Elavarasi, A; Kalaivani, M; Kumar Singh, R; Prarthana Chandra, P; Sagar, R; Tripathi, M; Vibha, D | 1 |
| Carhart-Harris, R; Carlbring, P; Davis, AK; Erritzoe, D; Goldberg, SB; Griffiths, RR; Nutt, DJ; Simonsson, O | 1 |
| Ahn, YM; Arumugham, SS; Ashok, MV; Beaulieu, S; Bhandary, RP; Bond, DJ; Daigneault, A; Frey, BN; Ha, K; Kesavan, M; Kondapuram, N; Lam, RW; Milev, R; Murthy, NS; Ouyang, Y; Ramachandran, K; Ravindran, A; Ravindran, N; Reddy, MS; Reddy, YCJ; Saraf, G; Schaffer, A; Wong, H; Yatham, LN | 1 |
| Cheng, PY; Hsiao, M; Lin, CC; Liu, YP; Yang, CP | 1 |
| Dong, K; Duan, W; Guo, R; Li, J; Li, Y; Ren, F; Wei, W; Yang, L; Zhao, Z | 1 |
| Lu, Z; Wang, Y; Xun, G | 1 |
| Bennett, SN; Cheng, CJ; Fiori, LM; Parel, ST; Peña, CJ; Timmermans, OC; Turecki, G | 1 |
| Ahn, Y; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Kim, SY; Lee, HJ; Lee, JY; Shin, HY; Shin, IS; Stewart, R; Yoon, JS | 1 |
| Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J | 1 |
| Amaro, E; Benseñor, IM; Brunoni, AR; Bueno, PV; Bulubas, L; Busatto, G; Duran, F; Gattaz, W; Goerigk, S; Keeser, D; Lotufo, PA; Mezger, E; Padberg, F; Suen, P | 1 |
| Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI | 1 |
| Belluomo, I; Bersani, G; Bigio, B; Bowles, NP; Caroti, E; Cuoco, V; Di Lallo, VD; Fanelli, F; Iannitelli, A; Marconi, M; Nasca, C; Nicoletti, F; Pacitti, F; Quartini, A; Weisz, F; Xenos, D | 1 |
| Booze, RM; Denton, AR; Harrod, SB; Lateef, AU; Mactutus, CF | 1 |
| Allen, TA; Frey, BN; Harkness, KL; Kennedy, SH; Lam, RW; Milev, R; Mueller, DJ; Quilty, LC; Uher, R | 1 |
| Blumenthal, JA; Davidson, J; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Liao, L; Sherwood, A; Smith, PJ; Watkins, LL | 1 |
| Gericke, J; Harvey, BH; Lekhooa, M; Steyn, SF; Viljoen, AM | 1 |
5 review(s) available for escitalopram and Depression
| Article | Year |
|---|---|
Psychological and pharmacological interventions for depression in patients with coronary artery disease.
Topics: Adult; Coronary Artery Disease; Depression; Escitalopram; Humans; Psychotherapy; Quality of Life | 2021 |
Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis.
Topics: Depression; Escitalopram; Humans; Incidence; Randomized Controlled Trials as Topic; Stroke | 2022 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
A systematic review and meta-analysis on the efficacy outcomes of selective serotonin reuptake inhibitors in depression in Alzheimer's disease.
Topics: Alzheimer Disease; Depression; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Sertraline | 2023 |
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Sample Size; Symptom Flare Up | 2023 |
15 trial(s) available for escitalopram and Depression
| Article | Year |
|---|---|
Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Escitalopram; Humans; Sertraline; Treatment Outcome | 2022 |
[Psilocybin compared with escitalopram for depression].
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry | 2022 |
Increased global integration in the brain after psilocybin therapy for depression.
Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin | 2022 |
Comparison of Functional and Structural Neural Network Features in Older Adults With Depression With vs Without Apathy and Association With Response to Escitalopram: Secondary Analysis of a Nonrandomized Clinical Trial.
Topics: Aged; Antidepressive Agents; Apathy; Depression; Depressive Disorder, Major; Escitalopram; Female; Humans; Neural Networks, Computer | 2022 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2023 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major; Escitalopram; Gyrus Cinguli; Humans; Magnetic Resonance Imaging | 2023 |
Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological | 2023 |
VE-MMODE - A randomized controlled trial of Venlafaxine versus Escitalopram for treatment of mild to moderate depression in persons with epilepsy.
Topics: Adolescent; Depression; Double-Blind Method; Epilepsy; Escitalopram; Humans; Seizures; Treatment Outcome; Venlafaxine Hydrochloride | 2023 |
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Canada; Depression; Double-Blind Method; Escitalopram; Humans; Mania; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2024 |
Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Depression; Escitalopram; Female; Humans; Male; Middle Aged; Prospective Studies; Republic of Korea; Selective Serotonin Reuptake Inhibitors | 2021 |
Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Memantine; Transcriptome; Treatment Outcome | 2021 |
Prefrontal resting-state connectivity and antidepressant response: no associations in the ELECT-TDCS trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Female; Gray Matter; Humans; Male; Prefrontal Cortex; Rest; Transcranial Direct Current Stimulation; Treatment Outcome | 2021 |
Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2021 |
Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial.
Topics: Aged; Anxiety Disorders; Comorbidity; Coronary Disease; Depression; Escitalopram; Exercise Therapy; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibitors | 2021 |
25 other study(ies) available for escitalopram and Depression
| Article | Year |
|---|---|
Psychiatry goes psychedelic.
Topics: Clinical Trials, Phase II as Topic; Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2021 |
Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report.
Topics: Anxiety; Depression; Depressive Disorder, Major; Escitalopram; Humans; Treatment Outcome | 2022 |
Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disks Large Homolog 4 Protein; Escitalopram; Excitatory Amino Acid Antagonists; Hindlimb Suspension; Ketamine; Male; Mice; Mice, Inbred C57BL; Prefrontal Cortex; Receptors, AMPA; Receptors, Metabotropic Glutamate; Selective Serotonin Reuptake Inhibitors; Social Defeat; Stress, Psychological | 2022 |
Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study.
Topics: Biomarkers; Canada; Depression; Depressive Disorder, Major; Escitalopram; Humans | 2023 |
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Escitalopram; Humans; Treatment Outcome | 2022 |
Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT study.
Topics: Brain; Depression; Depressive Disorder, Major; Escitalopram; Humans; Prospective Studies; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon | 2023 |
Decreased sensitivity to antidepressant drugs in Wistar Hannover rats submitted to two animal models of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Escitalopram; Fluoxetine; Imipramine; Models, Animal; Rats; Rats, Wistar; Swimming | 2023 |
Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression:
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort Studies; Depression; Escitalopram; Fluoxetine; Humans; Methylphenidate; Selective Serotonin Reuptake Inhibitors; Tic Disorders | 2023 |
Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study.
Topics: Citalopram; Cross-Sectional Studies; Depression; Escitalopram; Humans; Retrospective Studies; Treatment Failure | 2023 |
THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH.
Topics: COVID-19; Depression; Escitalopram; Humans; Quality of Life; Treatment Outcome | 2023 |
Long noncoding RNA NONHSAG045500 regulates serotonin transporter to ameliorate depressive-like behavior via the cAMP-PKA-CREB signaling pathway in a model of perinatal depression.
Topics: Animals; CREB-Binding Protein; Depression; Escitalopram; Female; Mice; Mice, Inbred C57BL; Pregnancy; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2023 |
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results | 2023 |
Do sociodemographic and clinical factors affect the selection of initial antidepressant treatment for depression in older adults? Results from a nationwide descriptive study in Denmark.
Topics: Aged; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Denmark; Depression; Escitalopram; Humans; Mirtazapine; Sertraline | 2023 |
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.
Topics: Animals; Citalopram; Depression; Disease Models, Animal; Escitalopram; gamma-Aminobutyric Acid; Glutamates | 2023 |
The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Antidepressive Agents; Depression; Escitalopram; Fluoxetine; Humans; Mice; Paraventricular Hypothalamic Nucleus; Paroxetine; Serotonin; Stress, Psychological | 2023 |
Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Ascorbic Acid; Cell Cycle Proteins; Citalopram; Depression; Escitalopram; Mice; Vitamin D; Vitamins | 2023 |
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2023 |
Selective serotonin reuptake inhibitors regulate the interrelation between 5-HT and inflammation after myocardial infarction.
Topics: Animals; Depression; Disease Models, Animal; Escitalopram; Inflammation; Interleukin-33; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Selective Serotonin Reuptake Inhibitors; Serotonin; Sucrose; Tumor Necrosis Factor-alpha | 2023 |
Escitalopram reversibility of the impacts following chronic stress on central 5-HT profiles - Implications to depression and anxiety.
Topics: Animals; Anxiety; Depression; Escitalopram; Hippocampus; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin | 2023 |
Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Astrocytes; Depression; Escitalopram; Hippocampus; Inflammation; Lipopolysaccharides; Mitophagy; Neurons; NF-kappa B; Pyroptosis; Rats; Reactive Oxygen Species | 2023 |
Transcriptional signatures of early-life stress and antidepressant treatment efficacy.
Topics: Adverse Childhood Experiences; Animals; Antidepressive Agents; Depression; Escitalopram; Female; Humans; Ketamine; Male; Mice; Stress, Psychological; Treatment Outcome | 2023 |
Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression.
Topics: Arachidonic Acids; Depression; Depressive Disorder, Major; Endocannabinoids; Escitalopram; Glycerides; Humans | 2021 |
Chronic SSRI treatment reverses HIV-1 protein-mediated synaptodendritic damage.
Topics: Animals; Antidepressive Agents; Apathy; Choice Behavior; Dendrites; Depression; Dopaminergic Neurons; Escitalopram; Female; HIV Infections; HIV-1; Humans; Male; Maze Learning; Nucleus Accumbens; Rats; Rats, Transgenic; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Synapses; Synaptic Transmission; Treatment Outcome | 2021 |
Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Escitalopram; Humans; Neuroticism | 2021 |
An acute dose-ranging evaluation of the antidepressant properties of Sceletium tortuosum (Zembrin®) versus escitalopram in the Flinders Sensitive Line rat.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Escitalopram; Male; Mass Spectrometry; Mesembryanthemum; Plant Extracts; Rats; South Africa | 2022 |